Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period
Latest Information Update: 17 Jan 2023
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms STEP 4
- Sponsors Novo Nordisk
- 16 Jan 2023 Results of exploratory analyses from STEP 1 and 4 ; evaluating the effects of once-weekly subcutaneous semaglutide 2.4 mg on cardiometabolic risk factors in people with overweight/obesity without diabetes, published in the Diabetes, Obesity and Metabolism
- 01 Dec 2022 Results assessing the safety and efficacy of a weekly 2.4-mg subcutaneous injection of semaglutide for chronic weight management in STEPS 1-4 studies, published in the American Journal of Managed Care.
- 23 Sep 2022 Results of two studies(STEP 1 and STEP 4) assessing the effect of Semaglutide 2.4 mg in reducing the 10-year type 2 diabetes risk in people with overweight or obesity presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.